Congestive Heart Failure Drugs Market, By Type (Left-sided Heart Failure, Right-sided Heart Failure, High-output Heart Failure), By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others), By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Congestive heart failure drugs Market size was valued at USD 6,600.9 Million in 2022, expanding at a CAGR of 15.8% from 2023 to 2030.
Congestive heart failure, a multifaceted clinical condition, arises from various cardiac issues, whether structural or functional, hindering the heart\'s ability to efficiently circulate blood throughout the body. The optimal approach to treating congestive heart failure depends on factors such as the underlying cause, its severity, and the presence of concurrent medical conditions in the patient. The primary objective in addressing chronic congestive heart failure is to enhance symptom control and elevate the patient\'s quality of life. This involves minimizing hospital admissions and reducing the overall mortality rate.
Congestive heart failure drugs Market- Market Dynamics
- A rise in the geriatric population and an increase in the incidence of hypertension, obesity, and diabetes are expected to augment industry growth.
The elderly population is often burdened with multiple concurrent illnesses and a higher intake of medications, rendering them more susceptible to drug interactions and conditions that can exacerbate heart failure. Additionally, obesity is associated with other health complications like sleep apnea and diabetes, both of which increase the risk of heart failure.
In 2020, the World Health Organization reported that 39 million children under the age of 5 were dealing with issues of overweight or obesity. As healthcare infrastructure in emerging economies continues to advance, there arises a growing demand for contemporary medical treatments, particularly medications for conditions such as congestive heart failure (CHF), offering promising avenues for market expansion. Nevertheless, advanced therapies like cardiac resynchronization therapy (CRT) and other medical devices can sometimes reduce the necessity for pharmaceutical interventions.
Congestive heart failure drugs Market- Key Insights
- According to insights provided by our research analysts, the global market for Congestive Heart Failure drugs is poised to experience substantial growth with an estimated annual CAGR of approximately 15.8% throughout the forecast period from 2023 to 2030.
- This industry is expected to witness significant expansion, driven by a growing awareness of sustainable healthcare solutions and the increasing prevalence of heart-related ailments. In terms of the type of heart failure, Left-sided Heart Failure emerged as the dominant category in the market in 2022.
- Regarding the classification of these drugs, Angiotensin II Receptor Blockers (ARBs) secured the leading position among drug classes in 2022. Furthermore, hospital pharmacies emerged as the primary distribution channel for these medications in the same year.
- Geographically, North America claimed the top spot as the region with the highest revenue generation in 2022, reflecting the region\'s substantial contribution to the market\'s overall growth.
Congestive Heart Failure Drugs Market- Segmentation Analysis:
The Congestive Heart Failure Drugs Market worldwide is structured around several key factors, including the type of heart failure, drug class, distribution channels, and regional distinctions. These components shape the dynamics of the market and offer diverse insights into its functioning.
Firstly, the market classification is based on the type of heart failure, with three primary categories: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure. Among these, Left-sided Heart Failure holds the highest prevalence. Additionally, Left-sided Heart Failure is further categorized into heart failures with reduced ejection fraction (HFrEF) and heart failures with maintained ejection fraction (HFpEF), each requiring tailored treatments.
This segmentation approach enables a more precise understanding of the market landscape and facilitates the development of targeted strategies to address the unique demands associated with each heart failure type.
Congestive heart failure drugs Market- Competitive Landscape:
The congestive heart failure (CHF) medications market boasts a diverse array of participants, spanning from established pharmaceutical giants to emerging players focused on cutting-edge therapies. Within this dynamic landscape, several leading pharmaceutical companies are actively engaged in the development of innovative CHF treatments. Simultaneously, there exists a significant market for generic medications, particularly due to the expiration of patents for many earlier CHF therapies.
The market has also witnessed a substantial number of mergers and acquisitions, with larger industry players strategically acquiring or collaborating with smaller firms to expand their pipelines with groundbreaking treatments. An illustrative case of this trend is the recent announcement by Merck, known as MSD outside the United States and Canada, on March 6, 2023. Merck revealed that the U.S. Food and Drug Administration (FDA) had granted approval for VERQUVO, a soluble guanylate cyclase (sGC) stimulator. This approval is significant as it pertains to reducing the risk of cardiovascular death and heart failure hospitalization for individuals with symptomatic chronic heart failure and ejection fraction less than 45% who have undergone hospitalization for heart failure or require outpatient intravenous (IV) diuretics. Such developments underscore the ever-evolving landscape of CHF medications, driven by a blend of innovation, consolidation, and the pursuit of advanced therapeutic solutions.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET KEY PLAYERS
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca
- Bristol-Myers Squibb Company
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- Novo Nordisk A/S
GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY TYPE
- Left-sided Heart Failure
- Right-sided Heart Failure
- High-output Heart Failure
GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DRUG CLASS
- ACE Inhibitors
- Angiotensin 2 Receptor Blockers
- Beta Blockers
- Diuretics
- Aldosterone Antagonists
- Inotropes
- Others
GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Congestive Heart Failure Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Congestive Heart Failure Drugs Market Snippet by Type
2.1.2. Congestive Heart Failure Drugs Market Snippet by Drug Class
2.1.3. Congestive Heart Failure Drugs Market Snippet by Distribution Channel
2.1.4. Congestive Heart Failure Drugs Market Snippet by Country
2.1.5. Congestive Heart Failure Drugs Market Snippet by Region
2.2. Competitive Insights
3. Congestive Heart Failure Drugs Key Market Trends
3.1. Congestive Heart Failure Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Congestive Heart Failure Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Congestive Heart Failure Drugs Market Opportunities
3.4. Congestive Heart Failure Drugs Market Future Trends
4. Congestive Heart Failure Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Congestive Heart Failure Drugs Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Congestive Heart Failure Drugs Market Landscape
6.1. Congestive Heart Failure Drugs Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Congestive Heart Failure Drugs Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
7.1.2. Left-sided Heart Failure
7.1.3. Right-sided Heart Failure
7.1.4. High-output Heart Failure
8. Congestive Heart Failure Drugs Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
8.1.2. ACE Inhibitors
8.1.3. Angiotensin 2 Receptor Blockers
8.1.4. Beta Blockers
8.1.5. Diuretics
8.1.6. Aldosterone Antagonists
8.1.7. Inotropes
8.1.8. Others
9. Congestive Heart Failure Drugs Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
9.1.2. Hospital Pharmacies
9.1.3. Retail Pharmacies
9.1.4. Online Pharmacies
10. Congestive Heart Failure Drugs Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Congestive Heart Failure Drugs Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Congestive Heart Failure Drugs Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Congestive Heart Failure Drugs Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Congestive Heart Failure Drugs Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Congestive Heart Failure Drugs Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Congestive Heart Failure Drugs Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Bayer AG
11.2.2. Novartis AG
11.2.3. Merck & Co., Inc.
11.2.4. AstraZeneca
11.2.5. Bristol-Myers Squibb Company
11.2.6. Amgen Inc.
11.2.7. Boehringer Ingelheim International GmbH
11.2.8. Pfizer, Inc.
11.2.9. Johnson & Johnson Services, Inc.
11.2.10. Otsuka Pharmaceutical Co., Ltd.
11.2.11. Eli Lilly and Company
11.2.12. Novo Nordisk A/S
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
